Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
March 26, 2007

Microtest to Manufacture First Anticancer Aptamer for Clinical Testing

  • Microtest signed a deal with Antisoma to immediately begin the aseptic manufacturing of AS1411, a drug being developed for the treatment of various cancers.

    “AS1411 is the first aptamer to be tested in cancer clinical trials. After successfully completing Phase I trials, we are now advancing to Phase II trials in renal cancer and AML,” says Glyn Edwards, Antisoma’s CEO.

    Microtest will be responsible for the formulation and aseptic fill/finish of AS1411 material supply for forthcoming Phase II trials. In addition, it will be responsible for stability testing of the AS1411 product.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.